Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 2 Completed University of Maryland, Baltimore National Cancer Institute (NCI) · collab University of Maryland Greenebaum Cancer Center · collab

Open-labelTreatment

Summary

RATIONALE: Thalidomide may slow the growth of cancer cells. Oblimersen may increase the effectiveness of thalidomide and dexamethasone by making cancer cells more sensitive to the drugs. PURPOSE: Phase II trial to study the effectiveness of combining thalidomide and dexamethasone with oblimersen in treating patients who have relapsed or refractory multiple myeloma.

Timeline

Start: 2002-09
Primary completion: 2006-01
Completion: 2006-01

Publications

Results Badros AZ, Goloubeva O, Rapoport AP, Ratterree B, Gahres N, Meisenberg B, Takebe N, Heyman M, Zwiebel J, Streicher H, Gocke CD, Tomic D, Flaws JA, Zhang B, Fenton RG. Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients. J Clin Oncol. 2005 Jun 20;23(18):4089-99. doi: 10.1200/JCO.2005.14.381. Epub 2005 May 2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dexamethasone	Small molecule	40 mg	Oral
Subject	Thalidomide	Other / unclassified	100 mg	Oral
Subject	Thalidomide	Other / unclassified	400 mg	Oral
Subject	oblimersen sodium	Antisense oligonucleotide	3 mg/kg	Intravenous
Subject	oblimersen sodium	Antisense oligonucleotide	7 mg/kg	Intravenous

Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Summary

Timeline

Publications

Drugs

Indications